These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37052803)
1. Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials. Auvin S; Nortvedt C; Fuller DS; Sahebkar F Epilepsia; 2023 Jul; 64(7):1812-1820. PubMed ID: 37052803 [TBL] [Abstract][Full Text] [Related]
2. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials. Privitera M; Bhathal H; Wong M; Cross JH; Wirrell E; Marsh ED; Mazurkiewicz-Beldzinska M; Villanueva V; Checketts D; Knappertz V; VanLandingham K Epilepsia; 2021 May; 62(5):1130-1140. PubMed ID: 33797076 [TBL] [Abstract][Full Text] [Related]
3. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K; Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273 [TBL] [Abstract][Full Text] [Related]
4. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy. Perry MS Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420 [TBL] [Abstract][Full Text] [Related]
5. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. Wheless JW; Isojarvi J; Lee D; Drummond R; Benbadis SR Epilepsy Behav; 2014 Dec; 41():47-52. PubMed ID: 25282105 [TBL] [Abstract][Full Text] [Related]
6. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V; JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035 [TBL] [Abstract][Full Text] [Related]
7. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey. Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688 [TBL] [Abstract][Full Text] [Related]
8. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022 [TBL] [Abstract][Full Text] [Related]
9. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM; N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152 [TBL] [Abstract][Full Text] [Related]
10. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. Madan Cohen J; Checketts D; Dunayevich E; Gunning B; Hyslop A; Madhavan D; Villanueva V; Zolnowska M; Zuberi SM Epilepsia; 2021 Sep; 62(9):2218-2227. PubMed ID: 34265088 [TBL] [Abstract][Full Text] [Related]
11. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695 [TBL] [Abstract][Full Text] [Related]
12. Anti-seizure medications for Lennox-Gastaut syndrome. Brigo F; Jones K; Eltze C; Matricardi S Cochrane Database Syst Rev; 2021 Apr; 4(4):CD003277. PubMed ID: 33825230 [TBL] [Abstract][Full Text] [Related]
13. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Wijnen B; Armstrong N; Ramaekers B; Witlox W; Westwood M; Fayter D; Ryder S; Buksnys T; Worthy G; Misso K; Grimm S; Kleijnen J; Joore M Pharmacoeconomics; 2020 Oct; 38(10):1043-1053. PubMed ID: 32514751 [TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis. Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269 [TBL] [Abstract][Full Text] [Related]
16. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis. Devi N; Madaan P; Ameen R; Sahu JK; Bansal D Seizure; 2022 Jul; 99():164-175. PubMed ID: 35487871 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833 [TBL] [Abstract][Full Text] [Related]
18. Cannabidiol - an effective analgesic for toothache? Murphy S; Hayes E Evid Based Dent; 2024 Jun; 25(2):100-101. PubMed ID: 38649735 [TBL] [Abstract][Full Text] [Related]
19. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234 [TBL] [Abstract][Full Text] [Related]
20. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]